Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Antenatal treatment in two Dutch families with pyridoxine-dependent seizures

Abstract

Incidental reports suggest that antenatal treatment of pyridoxine dependent seizures (PDS) may improve neurodevelopmental outcome of affected patients. Two families with PDS are reported, both with two affected siblings. Antenatal treatment with pyridoxine was instituted during the second pregnancy in each family (50 and 60 mg daily from 3 and 10 weeks of gestation, respectively). Perinatal characteristics and neurodevelopmental outcome at 4 (Family A) and 12 (Family B) years of age were compared between the untreated and treated child within each family. Meconium-stained amniotic fluid was present in both first pregnancies and abnormal foetal movements were noticed in one. In the treated infants, pregnancy and birth were uncomplicated. In family A, postnatal pyridoxine supplementation prevented neonatal seizures. Both children in family A were hypotonic and started walking after 2 years of age; both had white matter changes on MRI, and the first child was treated for squint. IQ was 73 and 98 in the antenatally untreated and treated child, respectively. The second child in family B developed seizures on the seventh day, because pyridoxine maintenance therapy had not been instituted after birth. Seizures responded rapidly to pyridoxine supplementation. MRI showed large ventricles and a mega cisterna magna. IQ was 80 and 106 in the antenatally untreated and treated child respectively. Both children had normal motor development. These results suggest that antenatal pyridoxine supplementation may be effective in preventing intrauterine seizures, decreasing the risk of complicated birth and improving neurodevelopmental outcome in PDS.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Ampola MG, Mahoney MJ, Nakamura E, Tanaka K (1975) Prenatal therapy of a patient with vitamin-B12-responsive methylmalonic acidemia. N Engl J Med 293:313–317

  2. 2.

    Bagci S, Zschocke J, Hoffmann GF, Bast T, Klepper J, Muller A, Heep A, Bartmann P, Franz AR (2008) Pyridoxal phosphate-dependent neonatal epileptic encephalopathy. Arch Dis Child Fetal Neonatal Ed 93:F151–F152

  3. 3.

    Baker H, Frank O, Deangelis B, Feingold S, Kaminetzky HA (1981) Role of placenta in maternal-fetal vitamin transfer in humans. Am J Obstet Gynecol 141:792–796

  4. 4.

    Baxter P (1999) Epidemiology of pyridoxine dependent and pyridoxine responsive seizures in the UK. Arch Dis Child 81:431–433

  5. 5.

    Baxter P, Griffiths P, Kelly T, Gardner-Medwin D (1996) Pyridoxine-dependent seizures: demographic, clinical, MRI and psychometric features, and effect of dose on intelligence quotient. Dev Med Child Neurol 38:998–1006

  6. 6.

    Baxter P (2001) Pyridoxine dependent and pyridoxine responsive seizures. In: Baxter P (ed) Vitamin responsive conditions in paediatric neurology. Mac Keith, London, pp 109–165

  7. 7.

    Been JV, Bok LA, Andriessen P, Renier WO (2005) Epidemiology of pyridoxine dependent seizures in the Netherlands. Arch Dis Child 90:1293–1296

  8. 8.

    Bejsovec M, Kulenda Z, Ponca E (1967) Familial intrauterine convulsions in pyridoxine dependency. Arch Dis Child 42:201–207

  9. 9.

    Bennett CL, Chen Y, Hahn S, Glass IA, Gospe SM Jr (2008) Prevalence of ALDH7A1 mutations in 18 North American pyridoxine-dependent seizure (PDS) patients. Epilepsia 50(5):1167–1175

  10. 10.

    Bok LA, Struys E, Willemsen MA, Been JV, Jakobs C (2007) Pyridoxine-dependent seizures in Dutch patients: diagnosis by elevated urinary alpha-aminoadipic semialdehyde levels. Arch Dis Child 92:687–689

  11. 11.

    Cleary RE, Lumeng L, Li TK (1975) Maternal and fetal plasma levels of pyridoxal phosphate at term: adequacy of vitamin B6 supplementation during pregnancy. Am J Obstet Gynecol 121:25–28

  12. 12.

    Coursin DB (1964) Vitamin B6 metabolism in infants and children. Vitam Horm 22:755–786

  13. 13.

    de Koning TJ, Klomp LW, van Oppen AC, Beemer FA, Dorland L, van der Berg I, Berger R (2004) Prenatal and early postnatal treatment in 3-phosphoglycerate-dehydrogenase deficiency. Lancet 364:2221–2222

  14. 14.

    Gospe SM (2002) Pyridoxine-dependent seizures: findings from recent studies pose new questions. Pediatr Neurol 26:181–185

  15. 15.

    Gospe SM Jr, Hecht ST (1998) Longitudinal MRI findings in pyridoxine-dependent seizures. Neurology 51:74–78

  16. 16.

    Haenggeli CA, Girardin E, Paunier L (1991) Pyridoxine-dependent seizures, clinical and therapeutic aspects. Eur J Pediatr 150:452–455

  17. 17.

    Hunt AD Jr, Stokes J Jr, McCrory WW, Stroud HH (1954) Pyridoxine dependency: report of a case of intractable convulsions in an infant controlled by pyridoxine. Pediatrics 13:140–145

  18. 18.

    Iinuma K, Narisawa K, Yamauchi N, Yoshida T, Mizuno T (1971) Pyridoxine dependent convulsion: effect of pyridoxine therapy on electroencephalograms. Tohoku J Exp Med 105:19–26

  19. 19.

    Jardim LB, Pires RF, Martins CE, Vargas CR, Vizioli J, Kliemann FA, Giugliani R (1994) Pyridoxine-dependent seizures associated with white matter abnormalities. Neuropediatrics 25:259–261

  20. 20.

    Kanno J, Kure S, Narisawa A, Kamada F, Takayanagi M, Yamamoto K, Hoshino H, Goto T, Takahashi T, Haginoya K, Tsuchiya S, Baumeister FA, Hasegawa Y, Aoki Y, Yamaguchi S, Matsubara Y (2007) Allelic and non-allelic heterogeneities in pyridoxine dependent seizures revealed by ALDH7A1 mutational analysis. Mol Genet Metab 91:384–389

  21. 21.

    Kort W, Schittekatte M, Dekker PH et al (2005) WISC-III NL; Wechsler intelligence scale for children, derde Editie NL. Harcourt Test, London

  22. 22.

    Kroll JS (1985) Pyridoxine for neonatal seizures: an unexpected danger. Dev Med Child Neurol 27:377–379

  23. 23.

    Lott IT, Coulombe T, Di Paolo RV, Richardson EP Jr, Levy HL (1978) Vitamin B6-dependent seizures: pathology and chemical findings in brain. Neurology 28:47–54

  24. 24.

    Mills PB, Struys E, Jakobs C, Plecko B, Baxter P, Baumgartner M, Willemsen MA, Omran H, Tacke U, Uhlenberg B, Weschke B, Clayton PT (2006) Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med 12:307–309

  25. 25.

    Nabbout R, Soufflet C, Plouin P, Dulac O (1999) Pyridoxine dependent epilepsy: a suggestive electroclinical pattern. Arch Dis Child Fetal Neonatal Ed 81:F125–F129

  26. 26.

    Tellegen PJ, Winkel M, Wijnberg-Williams BJ et al (1998) Snijders-Oomen Niet-verbale Intelligentietest, SON-R 2½-7. Swets & Zeitlinger B.V., Lisse

  27. 27.

    Parry GJ, Bredesen DE (1985) Sensory neuropathy with low-dose pyridoxine. Neurology 35:1466–1468

  28. 28.

    Pettit RE (1987) Pyridoxine dependency seizures: report of a case with unusual features. J Child Neurol 2:38–40

  29. 29.

    Plecko B, Paul K, Paschke E, Stoeckler-Ipsiroglu S, Struys E, Jakobs C, Hartmann H, Luecke T, di Capua M, Korenke C, Hikel C, Reutershahn E, Freilinger M, Baumeister F, Bosch F, Erwa W (2007) Biochemical and molecular characterization of 18 patients with pyridoxine-dependent epilepsy and mutations of the antiquitin (ALDH7A1) gene. Hum Mutat 28:19–26

  30. 30.

    Rankin PM, Harrison S, Chong WK, Boyd S, Aylett SE (2007) Pyridoxine-dependent seizures: a family phenotype that leads to severe cognitive deficits, regardless of treatment regime. Dev Med Child Neurol 49:300–305

  31. 31.

    Salomons GS, Bok LA, Struys EA, Pope LL, Darmin PS, Mills PB, Clayton PT, Willemsen MA, Jakobs C (2007) An intriguing "silent" mutation and a founder effect in antiquitin (ALDH7A1). Ann Neurol 62:414–418

  32. 32.

    Scriver CR (1960) Vitamin B6-dependency and infantile convulsions. Pediatrics 26:62–74

  33. 33.

    Shih JJ, Kornblum H, Shewmon DA (1996) Global brain dysfunction in an infant with pyridoxine dependency: evaluation with EEG, evoked potentials, MRI, and PET. Neurology 47:824–826

  34. 34.

    Tanaka R, Okumura M, Arima J, Yamakura S, Momoi T (1992) Pyridoxine-dependent seizures: report of a case with atypical clinical features and abnormal MRI scans. J Child Neurol 7:24–28

  35. 35.

    Tang WK, Wong KB, Lam YM, Cha SS, Cheng CH, Fong WP (2008) The crystal structure of seabream antiquitin reveals the structural basis of its substrate specificity. FEBS Lett 582:3090–3096

  36. 36.

    van Waarde WM, Tummers RF, Bosschaart AN, Hageman G (1995) Pyridoxine-dependent epilepsy in an infant. Ned Tijdschr Geneeskd 139:1694–1697

Download references

Conflict of Interest

All authors declare that they have no conflict of interest. This study was not financially sponsored.

Author information

Correspondence to Levinus A. Bok.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bok, L.A., Been, J.V., Struys, E.A. et al. Antenatal treatment in two Dutch families with pyridoxine-dependent seizures. Eur J Pediatr 169, 297–303 (2010). https://doi.org/10.1007/s00431-009-1020-2

Download citation

Keywords

  • Seizures
  • Pyridoxine
  • Antenatal treatment
  • Development